Subcutaneous absorption of biotherapeutics: Knowns and unknowns

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1881-1889

  Richter, Wolfgang F ^a   Jacobsen, Björn ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; DENOSUMAB; ETANERCEPT; GOLIMUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; RECOMBINANT PROTEIN; RILONACEPT; RITUXIMAB; ROMIPLOSTIM; TOCILIZUMAB; TRASTUZUMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DIFFUSION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; EXTRACELLULAR MATRIX; HUMAN; LYMPHATIC SYSTEM; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; SKIN ABSORPTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL PRODUCTS; HUMANS; INFUSIONS, SUBCUTANEOUS; SKIN ABSORPTION;

EID: 84930887027     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059238     Document Type: Short Survey

References (59)

1. Aukland K and Reed RK (1993) Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 73:1-78.
2. Bantle JP, Neal L, and Frankamp LM (1993) Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 16:1592-1597.
3. Berger M, Halban PA, Girardier L, Seydoux J, Offord RE, and Renold AE (1979) Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site. Diabetologia 17:97-99.
4. Berk DA, Swartz MA, Leu AJ, and Jain RK (1996) Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 270:H330-H337.
5. Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, and Schmidt J (2014) Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg) 2014:22 Epub ahead of print.
6. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, and Schmidt J (2012) Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 62:401-409.
7. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, and Frost GI (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230-241.
8. Charman SA, Segrave AM, Edwards GA, and Porter CJ (2000) Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci 89:168-177.
9. Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, and Braeckman RA (2000) Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J Pharmacol Exp Ther 293:248-259.
10. Dahlberg AM, Kaminskas LM, Smith A, Nicolazzo JA, Porter CJ, Bulitta JB, and McIntosh MP (2014) The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. Mol Pharm 11:496-504.
11. Datta-Mannan A, Witcher DR, Lu J, and Wroblewski VJ (2012) Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267-273.
12. Davis CB and Bugelski PJ (1998) Subcutaneous bioavailability of a PRIMATIZED IgG1 antihuman CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4. Drug Deliv 5:95-100.
13. Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, and Prabhu S (2012) Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 4:101-109.
14. Filipe V, Que I, Carpenter JF, Löwik C, and Jiskoot W (2014) In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice. Pharm Res 31:216-227.
15. Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4:427-440.
16. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, and Moreton P, et al. (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948-955.
17. Hollander W, Reilly P, and Burrows BA (1961) Lymphatic flow in human subjects as indicated by the disappearance of 1-131-labeled albumin from the subcutaneous tissue. J Clin Invest 40:222-233.
18. Hunter J (2008) Subcutaneous injection technique. Nurs Stand 22:41-44.
19. Jensen JD, Jensen LW, and Madsen JK (1994) The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 46:333-337.
20. Jørgensen JT, Rømsing J, Rasmussen M, Møller-Sonnergaard J, Vang L, and Musaeus L (1996) Pain assessment of subcutaneous injections. Ann Pharmacother 30:729-732.
21. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, and Hoffman A (2007) The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 67:759-765.
22. Kagan L and Mager DE (2013) Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos 41:248-255.
23. Kagan L, Turner MR, Balu-Iyer SV, and Mager DE (2012) Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 29:490-499.
24. Kawashima S, Kaneto H, Sakamoto K, Honsho I, Yasuda T, Kuroda A, Shiraiwa T, Kasami R, Matsuoka TA, and Yamasaki Y, et al. (2008) Dramatic improvement of subcutaneous insulin resistance with nafamostat ointment treatment. Diabetes Care 31:e11 10.2337/dc07-2161.
25. Kinnunen HM and Mrsny RJ (2014) Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release 182:22-32 10.1016/j.jconrel.2014.03.011.
26. Kojima K, Takahashi T, and Nakanishi Y (1988) Lymphatic transport of recombinant human tumor necrosis factor in rats. J Pharmacobiodyn 11:700-706.
27. Komada F, Okumura K, and Hori R (1985) Fate of porcine and human insulin at the subcutaneous injection site. II. In vitro degradation of insulins in the subcutaneous tissue of the rat. J Pharmacobiodyn 8:33-40.
28. Launay-Vacher V (2013) An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. Cancer Chemother Pharmacol 72:1361-1367.
29. Laursen T, Jørgensen JO, and Christiansen JS (1994) Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clin Endocrinol (Oxf) 40:373-378.
30. Lubach D, Nissen S, and Neukam D (1991) Demonstration of initial lymphatics in excised human skin using an extension technique and dye injection. J Invest Dermatol 96:754-757.
31. Mach H, Gregory SM, Mackiewicz A, Mittal S, Lalloo A, Kirchmeier M, and Shameem M (2011) Electrostatic interactions of monoclonal antibodies with subcutaneous tissue. Ther Deliv 2:727-736.
32. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res 19:1537-1543.
33. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, and Ivens IA (2010) Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 12:461-470.
34. McLennan DN, Porter CJH, and Charman SA (2005) Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2:89-96.
35. McLennan DN, Porter CJ, Edwards GA, Martin SW, and Charman SA (2002) Molecular weight is a primary determinant for lymphatic absorption of proteins following subcutaneous administration to sheep. AAPS PharmSci 4:W4041.
36. Modi S, Stanton AWB, Svensson WE, Peters AM, Mortimer PS, and Levick JR (2007) Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy. J Physiol 583:271-285.
37. Muchmore DB and Vaughn DE (2010) Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Tech 4:419-428.
38. Negrini D, Tenstad O, and Wiig H (2003) Interstitial exclusion of albumin in rabbit lung during development of pulmonary oedema. J Physiol 548:907-917.
39. Reddy ST, Berk DA, Jain RK, and Swartz MA (2006) A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J Appl Physiol (1985) 101:1162-1169.
40. Richter WF, Bhansali SG, and Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559-570.
41. Richter WF, Gruyer M-S, and Birnböck H(2014). Marked contribution of lymphatic route in the SC absorption of an IgG fusion protein in the rabbit. AAPS National Biotech Conference 2014, May 19-21, 2014, San Diego, USA.
42. Ryan TJ (1989) Structure and function of lymphatics. J Invest Dermatol 93(2, Suppl):18S-24S.
43. Schweighofer CD and Wendtner CM (2010) First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther 3:53-67.
44. Skobe M and Detmar M (2000) Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 5:14-19.
45. Supersaxo A, Hein WR, and Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-169.
46. Swabb EA, Wei J, and Gullino PM (1974) Diffusion and convection in normal and neoplastic tissues. Cancer Res 34:2814-2822.
47. Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20.
48. Takeyama M, Ishida T, Kokubu N, Komada F, Iwakawa S, Okumura K, and Hori R (1991) Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors. Pharm Res 8:60-64.
49. Tilney NL (1971) Patterns of lymphatic drainage in the adult laboratory rat. J Anat 109:369-383.
50. Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, and Nunes CN, et al. (2012) Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 40:952-962.
51. Wang W, Wang EQ, and Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558.
52. Waterhouse J, Sawdon M, and Kirkman E (2010). Capillary dynamics and the interstitial fluid-lymphatic system. Anesth Intensive Care Med 11:69-74.
53. Wiig H and Swartz MA (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 92:1005-1060.
54. Woo S and Jusko WJ (2007) Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672-1678.
55. Wu F, Bhansali SG, Law WC, Bergey EJ, Prasad PN, and Morris ME (2012) Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res 29:1843-1853.
56. Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, Marini JC, Keen M, Snead D, and Davis HM, et al. (2010) Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 50:276-284.
57. Zhao L, Ji P, Li Z, Roy P, and Sahajwalla CG (2013) The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol 53:314-325.
58. Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, and Fielder PJ, et al. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 4:243-255.
59. Zou Y, Bateman TJ, Adreani C, Shen X, Cunningham PK, Wang B, Trinh T, Christine A, Hong X, and Nunes CN, et al. (2013) Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats. Drug Metab Dispos 41:2206-2214.